Using Nitazoxanide to Help Manage Type 2 Diabetes
A Clinical Study Evaluating the Potential Benefit of Nitazoxanide in Patients With Type 2 Diabetes Mellitus
PHASE2 · Tanta University · NCT06010992
This study is testing if adding the drug nitazoxanide can help people with type 2 diabetes better control their blood sugar levels.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University (other) |
| Locations | 2 sites (Tanta, El-Gharbia and 1 other locations) |
| Trial ID | NCT06010992 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of nitazoxanide, an anti-infective drug, as an additional treatment for patients with type 2 diabetes mellitus who have not achieved optimal glycemic control. The study focuses on patients with a glycated hemoglobin (HbA1c) level between 7% and 9% and a body mass index of 25 kg/m2 or higher. By assessing the drug's impact on insulin sensitivity, the trial aims to provide a new therapeutic option for managing this complex metabolic disorder.
Who should consider this trial
Good fit: Ideal candidates are adults with type 2 diabetes mellitus, a HbA1c between 7% and 9%, and a body mass index of 25 kg/m2 or higher.
Not a fit: Patients with type 1 diabetes, significant liver or kidney disease, or those who are pregnant or nursing may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve glycemic control in patients with type 2 diabetes who struggle with existing therapies.
How similar studies have performed: While nitazoxanide has shown promise in improving insulin sensitivity in animal models, this approach in humans is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Glycated hemoglobin (HbA1c) between 7% and 9%. * Body mass index ≥ 25 kg/m2 Exclusion Criteria: * Pregnant or nursing women. * Type 1 diabetes mellitus. * Liver disease (alanine aminotransferase \> 3 upper normal limit). * Kidney disease (estimated glomerular filtration rate \< 60 ml/min/1.73 m2). * Inflammatory bowel diseases. * History of allergy and/or adverse reactions to the drugs used in the study.
Where this trial is running
Tanta, El-Gharbia and 1 other locations
- Faculty of medicine, Tanta University — Tanta, El-Gharbia, Egypt (RECRUITING)
- Faculty of Medicine, Menoufia University — Shibīn Al Kawm, Menoufia, Egypt (RECRUITING)
Study contacts
- Principal investigator: Eman Ghonaim — Assistant Lecturer, Faculty of Pharmacy, Tanta University
- Study coordinator: Eman Ghonaim, Assistant lecturer
- Email: eman.ghonim@pharm.tanta.edu.eg
- Phone: +20-010-970-821-57
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Diabetes Mellitus, Type 2